Home › Conferences › EASD
European Association for the Study of Diabetes 2026
European Association for the Study of Diabetes 2026 took place September 28 to October 2, 2026 in Milan, IT.
Sep 28-Oct 2, 2026 · Milan, IT · Diabetes and metabolic.
DatesSep 28-Oct 2, 2026
LocationMilan, IT
Therapeutic focusDiabetes and metabolic
Biotech presenters sourced3
Organisereasd.org
Biotech presenters
IBIO
IBIO-610 (Activin E antibody) - PRECLINICAL; presentation #759 (preclinical) · source
IPSCCNTY-813 (iPSC-derived islet replacement) - PRECLINICAL; oral #225 (preclinical) · source
SANAUP421 (hypoimmune allogeneic islet cell therapy); symposium presentation · source
Each presenter is sourced to the company's own filing or release naming this meeting; this is not the organiser's programme, and abstract titles are embargoed until the organiser publishes them.
Filings that mention EASD 2026
A filing that names the meeting is not a commitment to present; these are listed with the sentence, for the reader to judge.
- KLRA: “• Phase 1 ribupatide injection site trial data to be presented at the 2026 European Association for the Study of Diabetes Annual Meeting (EASD): The oral presentation titled “Effect of Injection Site ” filing
About · Corrections · Changelog · Glossary · Methodology
Not affiliated with EASD or its organizer. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.
© 2026 pdufa.bio. All rights reserved.
Not affiliated with EASD or its organizer. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.
© 2026 pdufa.bio. All rights reserved.
What presenting companies' shares did, across the whole study
Across 1,425 presentations at major medical meetings from 2017 to 2026, the median presenting company's stock moved −0.03% in the 30 trading days before the meeting (49.8% rose) and −1.59% in the 5 trading days after (39.4% rose). Small caps: +2.75% before (n=298); nano caps: −7.86% (n=108). The middle half of all presenters ranged from −10.41% to +13.58%. The study is anchored on the meeting start date, not on the abstract release; the true catalyst may be earlier. This measures what happened; it is not a forecast for any company. Full study, with the method and its limits.
How EASD stocks have traded historically
Median share-price move around a presentation, measured across 1425 all tracked conference presentations in our study (2017-2026), because our study holds fewer than 12 EASD events on their own.
30 days before-0.03% 50% rose · n=1425
10 days before+0.63% 52% rose · n=1425
Presentation day-0.56% 44% rose · n=1425
5 days after-1.59% 39% rose · n=1425
10 days after-1.93% 40% rose · n=1425
Read the whole row, not just the first line: across this study stocks have drifted up into these meetings and down out of them, and the effect is largest in the smallest companies. Medians are shown because a handful of large moves pulls an average away from the typical case. This is a historical distribution for a cohort of companies, not a forecast for any single company, and not investment advice. Methodology and the full study.
FAQ
When is EASD 2026?
European Association for the Study of Diabetes 2026 runs September 28, 2026: October 2, 2026 in Milan, IT. The date comes from the organiser's own announcement; check the organiser's site for the final programme.
Which biotech companies are presenting at EASD 2026?
From company filings and releases we have sourced 4 presenter commitments for this edition: IBIO, IPSC, KLRA, SANA. This is not the organiser's programme -- only presentations companies have themselves announced, each linked to its filing on the conferences page.
Why do medical conference dates matter for biotech stocks?
Trial results are often presented first at medical meetings, so a company's announced presentation is a dated, public catalyst. We publish a study of how biotech stocks have historically traded into conference presentations on the research page; it is historical measurement, not a prediction, and none of this is investment advice.